Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Journal of Interventional Cardiac Electrophysiology
Erschienen in: Journal of Interventional Cardiac Electrophysiology 3/2019

03.07.2019 | MULTIMEDIA REPORT

Irreversible electroporation for catheter-based cardiac ablation: a systematic review of the preclinical experience

verfasst von: Alan Sugrue, Vaibhav Vaidya, Chance Witt, Christopher V. DeSimone, Omar Yasin, Elad Maor, Ammar M. Killu, Suraj Kapa, Christopher J. McLeod, Damijan Miklavčič, Samuel J. Asirvatham

Erschienen in: Journal of Interventional Cardiac Electrophysiology | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Irreversible electroporation (IRE) utilizing high voltage pulses is an emerging strategy for catheter-based cardiac ablation with considerable growth in the preclinical arena.

Methods

A systematic search for articles was performed from three sources (PubMed, EMBASE, and Google Scholar). The primary outcome was the efficacy of tissue ablation with characteristics of lesion formation evaluated by histologic analysis. The secondary outcome was focused on safety and damage to collateral structures.

Results

Sixteen studies met inclusion criteria. IRE was most commonly applied to the ventricular myocardium (n = 7/16, 44%) by a LifePak 9 Defibrillator (n = 9/16, 56%), NanoKnife Generator (n = 2/16, 13%), or other custom generators (n = 5/16, 31%). There was significant heterogeneity regarding electroporation protocols. On histological analysis, IRE was successful in creating ablation lesions with variable transmurality depending on the electric pulse parameters and catheter used.

Conclusion

Preclinical studies suggest that cardiac tissue ablation using IRE shows promise in delivering efficacious, safe lesions.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Edmonds JH, Ellison RG, Crews TL. Surgically induced atrioventricular block as treatment for recurrent atrial tachycardia in Wolff-Parkinson-White syndrome. Circulation. 1969;39(5S1):I-105–I-11.CrossRef
2.
Calkins H, Leon AR, Deam AG, Kalbfleisch SJ, Langberg JJ, Morady F. Catheter ablation of atrial flutter using radiofrequency energy. Am J Cardiol. 1994;73(5):353–6.CrossRefPubMed
3.
Swartz J. A catheter-based curative approach to atrial fibrillation in humans. Circulation. 1994;90:I-335.
4.
Jai P, Hai M, Shah DC, Chouairi S, Gencel L, Cle J. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation. 1997;95(3):572–6.CrossRef
5.
Haissaguerre M, Gencel L, Fischer B, Le Metayer P, Poquet F, Marcus FI, et al. Successful catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 1994;5(12):1045–52.CrossRefPubMed
6.
Hindricks G, Haverkamp W, Rissel U, Richter K, Gülker H. Experimental observations on the use of radiofrequency energy for ablation of ventricular tissue. New Trends Arrhyt. 1988;4(1–2):337–42.
7.
Gonska B, Brune S, Bethge K, Kreuzer H. Radiofrequency catheter ablation in recurrent ventricular tachycardia. Eur Heart J. 1991;12(12):1257–65.CrossRefPubMed
8.
Nathan AW, Bennett DH, Ward DE, Bexton RS, Camm AJ. Catheter ablation of atrioventricular conduction. Lancet (London, England). 1984;1(8389):1280–4.CrossRef
9.
Gallagher JJ, Svenson RH, Kasell JH, German LD, Bardy GH, Broughton A, et al. Catheter technique for closed-chest ablation of the atrioventricular conduction system: a therapeutic alternative for the treatment of refractory supraventricular tachycardia. N Engl J Med. 1982;306(4):194–200.CrossRefPubMed
10.
Ward DE, Davies M. Transvenous high energy shock for ablating atrioventricular conduction in man. Observations on the histological effects. Heart. 1984;51(2):175–8.CrossRef
11.
Huang SKS. Advances in applications of radiofrequency current to catheter ablation therapy. Pacing Clin Electrophysiol. 1991;14(1):28–42.CrossRefPubMed
12.
Olgin JE, Scheinman MM. Comparison of high energy direct current and radiofrequency catheter ablation of the atrioventricular junction. J Am Coll Cardiol. 1993;21(3):557–64.CrossRefPubMed
13.
Pappone C, Oral H, Santinelli V, Vicedomini G, Lang CC, Manguso F, et al. Atrio-esophageal fistula as a complication of percutaneous transcatheter ablation of atrial fibrillation. Circulation. 2004;109(22):2724–6.CrossRefPubMed
14.
Black-Maier E, Pokorney SD, Barnett AS, Zeitler EP, Sun AY, Jackson KP, et al. Risk of atrioesophageal fistula formation with contact force-sensing catheters. Heart Rhythm. 2017;14(9):1328–33.CrossRefPubMed
15.
Sacher F, Monahan KH, Thomas SP, Davidson N, Adragao P, Sanders P, et al. Phrenic nerve injury after atrial fibrillation catheter ablation: characterization and outcome in a multicenter study. J Am Coll Cardiol. 2006;47(12):2498–503.CrossRefPubMed
16.
Calkins H, Reynolds MR, Spector P, Sondhi M, Xu Y, Martin A, Williams CJ, Sledge I. Treatment of atrial fibrillation with anti–arrhythmic drugs or radio frequency ablation: two systematic literature reviews and meta–analyses. Circ Arrhythm Electrophysiol. 2009:CIRCEP. 108.824789.
17.
Schrickel JW, Lickfett L, Lewalter T, Mittman-Braun E, Selbach S, Strach K, et al. Incidence and predictors of silent cerebral embolism during pulmonary vein catheter ablation for atrial fibrillation. Europace. 2010;12(1):52–7.CrossRefPubMed
18.
Medi C, Evered L, Silbert B, Teh A, Halloran K, Morton J, et al. Subtle post-procedural cognitive dysfunction after atrial fibrillation ablation. J Am Coll Cardiol. 2013;62(6):531–9.CrossRefPubMed
19.
Andrade JG, Dubuc M, Guerra PG, Macle L, Mondésert B, Rivard L, et al. The biophysics and biomechanics of cryoballoon ablation. Pacing Clin Electrophysiol. 2012;35(9):1162–8.CrossRefPubMed
20.
Furnkranz A, Bordignon S, Bohmig M, Konstantinou A, Dugo D, Perrotta L, et al. Reduced incidence of esophageal lesions by luminal esophageal temperature-guided second-generation cryoballoon ablation. Heart Rhythm. 2015;12(2):268–74.CrossRefPubMed
21.
Narui R, Tokuda M, Matsushima M, Isogai R, Tokutake K, Yokoyama K, et al. Incidence and factors associated with the occurrence of pulmonary vein narrowing after cryoballoon ablation. Circ Arrhythm Electrophysiol. 2017;10(6).
22.
Ichihara N, Miyazaki S, Iwasawa J, Matsuda J, Taniguchi H, Nakamura H, et al. Prevalence and pre-procedural predictors associated with right phrenic nerve injury in electromyography-guided, second-generation cryoballoon ablation. JACC Clin Electrophysiol. 2016;2(4):508–14.CrossRefPubMed
23.
Aksu T, Ebru Golcuk S, Yalin K. Haemoptysis and pulmonary haemorrhage associated with cryoballoon ablation. Europace. 2015;17(8):1240.CrossRefPubMed
24.
Rems L, Miklavčič D. Tutorial: electroporation of cells in complex materials and tissue. J Appl Phys. 2016;119(20):201101.CrossRef
25.
Martin RC, McFarland K, Ellis S, Velanovich V. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann Surg Oncol. 2013;20(3):443–9.CrossRef
26.
Paiella S, Butturini G, Frigerio I, Salvia R, Armatura G, Bacchion M, et al. Safety and feasibility of irreversible electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study. Dig Surg. 2015;32(2):90–7.CrossRefPubMed
27.
Valerio M, Stricker PD, Ahmed HU, Dickinson L, Ponsky L, Shnier R, et al. Initial assessment of safety and clinical feasibility of irreversible electroporation in the focal treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2014;17(4):343–7.CrossRefPubMedPubMedCentral
28.
Scheffer HJ, Nielsen K, de Jong MC, van Tilborg AA, Vieveen JM, Bouwman AR, et al. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol. 2014;25(7):997–1011.CrossRefPubMed
29.
Welden CV, Christein JD, Wilcox CM, Ahmed AM. Initial experience of irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma. Gastroenterology. 2017;152(5):S277.CrossRef
30.
Wojtaszczyk A, Caluori G, Pesl M, Melajova K, Starek Z. Irreversible electroporation ablation for atrial fibrillation. J Cardiovasc Electrophysiol. 2018;29(4):643–51.CrossRefPubMed
31.
Sugrue A, Maor E, Ivorra A, Vaidya V, Witt C, Kapa S, et al. Irreversible electroporation for the treatment of cardiac arrhythmias. Expert Rev Cardiovasc Ther. 2018;16(5):349–60.CrossRefPubMed
32.
Reddy VY, Koruth J, Jais P, Petru J, Timko F, Skalsky I, et al. Ablation of atrial fibrillation with pulsed electric fields: an ultra-rapid, tissue-selective modality for cardiac ablation. JACC Clin Electrophysiol. 2018:674.
33.
Vries R, Hooijmans CR, Langendam MW, Luijk J, Leenaars M, Ritskes-Hoitinga M, et al. A protocol format for the preparation, registration and publication of systematic reviews of animal intervention studies. Evid Based Preclin Med. 2015;2(1):1–9.CrossRef
34.
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.CrossRefPubMedPubMedCentral
35.
Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412.CrossRefPubMedPubMedCentral
36.
DeSimone CV, Ebrille E, Syed FF, Mikell SB, Suddendorf SH, Wahnschaffe D, et al. Novel balloon catheter device with pacing, ablating, electroporation, and drug-eluting capabilities for atrial fibrillation treatment--preliminary efficacy and safety studies in a canine model. Transl Res. 2014;164(6):508–14.CrossRefPubMedPubMedCentral
37.
du Pre BC, van Driel VJ, van Wessel H, Loh P, Doevendans PA, Goldschmeding R, et al. Minimal coronary artery damage by myocardial electroporation ablation. Europace. 2013;15(1):144–9.CrossRefPubMed
38.
Hong J, Stewart MT, Cheek DS, Francischelli DE, Kirchhof N. Cardiac ablation via electroporation. Conf Proc IEEE Eng Med Biol Soc. 2009;2009:3381–4.
39.
Lavee J, Onik G, Mikus P, Rubinsky B, editors. A novel nonthermal energy source for surgical epicardial atrial ablation: irreversible electroporation. Heart Surgery Forum; 2007: FORUM MULTIMEDIA PUBLISHING.
40.
Madhavan M, Venkatachalam K, Swale MJ, Desimone CV, Gard JJ, Johnson SB, et al. Novel percutaneous epicardial autonomic modulation in the canine for atrial fibrillation: results of an efficacy and safety study. Pacing Clin Electrophysiol. 2016;39(5):407–17.CrossRefPubMedPubMedCentral
41.
Neven K, van Driel V, van Wessel H, van Es R, Doevendans PA, Wittkampf F. Epicardial linear electroporation ablation and lesion size. Heart Rhythm. 2014;11(8):1465–70.CrossRefPubMed
42.
Neven K, van Driel V, van Wessel H, van Es R, Doevendans PA, Wittkampf F. Myocardial lesion size after epicardial electroporation catheter ablation following subxiphoid puncture. Circ Arrhythm Electrophysiol. 2014:CIRCEP. 114.001659.
43.
Neven K, van Driel V, van Wessel H, van Es R, du Pre B, Doevendans PA, et al. Safety and feasibility of closed chest epicardial catheter ablation using electroporation. Circ Arrhythm Electrophysiol. 2014;7(5):913–9.CrossRefPubMed
44.
van Driel VJ, Neven K, van Wessel H, Vink A, Doevendans PA, Wittkampf FH. Low vulnerability of the right phrenic nerve to electroporation ablation. Heart Rhythm. 2015;12(8):1838–44.CrossRefPubMed
45.
van Driel VJ, Neven KG, van Wessel H, du Pre BC, Vink A, Doevendans PA, et al. Pulmonary vein stenosis after catheter ablation: electroporation versus radiofrequency. Circ Arrhythm Electrophysiol. 2014;7(4):734–8.CrossRefPubMed
46.
Wittkampf FH, van Driel VJ, van Wessel H, Neven KG, Grundeman PF, Vink A, et al. Myocardial lesion depth with circular electroporation ablation. Circ Arrhythm Electrophysiol. 2012;5(3):581–6.CrossRefPubMed
47.
Wittkampf FH, van Driel VJ, van Wessel H, Vink A, Hof IE, Grundeman PF, et al. Feasibility of electroporation for the creation of pulmonary vein ostial lesions. J Cardiovasc Electrophysiol. 2011;22(3):302–9.CrossRefPubMed
48.
Zager Y, Kain D, Landa N, Leor J, Maor E. Optimization of irreversible electroporation protocols for in-vivo myocardial decellularization. PLoS One. 2016;11(11):e0165475. PMCID: PMC5125564 a patent application entitled “Myocardial Ablation by Irreversible Electroporation” (Application #: US14/894,349). This patent relates in part to the results presented in this study. In addition, Dr. Maor has a granted patent entitled “Extracellular matrix material created using non-thermal irreversible electroporation” (US8835166 B2). There are no additional patents, products in development or marketed products to declare. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
49.
Neven K, van Es R, van Driel V, van Wessel H, Fidder H, Vink A, et al. Acute and long-term effects of full-power electroporation ablation directly on the porcine esophagus. Circ Arrhythm Electrophysiol. 2017;10(5):e004672.CrossRefPubMed
50.
Livia C, Sugrue A, Witt T, Polkinghorne MD, Maor E, Kapa S, et al. Elimination of Purkinje fibers by electroporation reduces ventricular fibrillation vulnerability. J Am Heart Assoc. 2018;7(15):e009070.CrossRefPubMedPubMedCentral
51.
Witt CM, Sugrue A, Padmanabhan D, Vaidya V, Gruba S, Rohl J, et al. Intrapulmonary vein ablation without stenosis: a novel balloon-based direct current electroporation approach. J Am Heart Assoc. 2018;7(14):e009575.CrossRefPubMedPubMedCentral
52.
Thomson KR, Cheung W, Ellis SJ, Federman D, Kavnoudias H, Loader-Oliver D, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol. 2011;22(5):611–21.CrossRefPubMed
53.
Charpentier KP, Wolf F, Noble L, Winn B, Resnick M, Dupuy DE. Irreversible electroporation of the liver and liver hilum in swine. HPB. 2011;13(3):168–73.CrossRefPubMedPubMedCentral
54.
Cannon R, Ellis S, Hayes D, Narayanan G, Martin RC 2nd. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol. 2013;107(5):544–9.CrossRefPubMed
55.
Mali B, Gorjup V, Edhemovic I, Brecelj E, Cemazar M, Sersa G, et al. Electrochemotherapy of colorectal liver metastases-an observational study of its effects on the electrocardiogram. Biomed Eng Online. 2015;14(3):S5.CrossRefPubMedPubMedCentral
56.
Bertacchini C, Margotti PM, Bergamini E, Lodi A, Ronchetti M, Cadossi R. Design of an irreversible electroporation system for clinical use. Technol Cancer Res Treat. 2007;6(4):313–20.CrossRefPubMed
57.
Deodhar A, Dickfeld T, Single GW, Hamilton WC Jr, Thornton RH, Sofocleous CT, et al. Irreversible electroporation near the heart: ventricular arrhythmias can be prevented with ECG synchronization. Am J Roentgenol. 2011;196(3):W330–W5.CrossRef
58.
Reberšek M. Beyond electroporation pulse parameters: from application to evaluation. Handb Electroporation. 2017:1–21.
59.
Schoenbach KH. From the basic science of biological effects of ultrashort electrical pulses to medical therapies. Bioelectromagnetics. 2018;39:257–76.CrossRefPubMed
60.
Mercadal B, Arena CB, Davalos RV, Ivorra A. Avoiding nerve stimulation in irreversible electroporation: a numerical modeling study. Phys Med Biol. 2017;62(20):8060–79.CrossRefPubMedPubMedCentral
61.
Raso J, Frey W, Ferrari G, Pataro G, Knorr D, Teissie J, et al. Recommendations guidelines on the key information to be reported in studies of application of PEF technology in food and biotechnological processes. Innovative Food Sci Emerg Technol. 2016;37:312–21.CrossRef
62.
Cemazar M, Sersa G, Frey W, Miklavcic D, Teissié J. Recommendations and requirements for reporting on applications of electric pulse delivery for electroporation of biological samples. Bioelectrochemistry. 2018;122:69–76.CrossRefPubMed
63.
Campana LG, Clover AJ, Valpione S, Quaglino P, Gehl J, Kunte C, et al. Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review. Radiol Oncol. 2016;50(1):1–13.CrossRefPubMedPubMedCentral
Metadaten
Titel
Irreversible electroporation for catheter-based cardiac ablation: a systematic review of the preclinical experience
verfasst von
Alan Sugrue
Vaibhav Vaidya
Chance Witt
Christopher V. DeSimone
Omar Yasin
Elad Maor
Ammar M. Killu
Suraj Kapa
Christopher J. McLeod
Damijan Miklavčič
Samuel J. Asirvatham
Publikationsdatum
03.07.2019
Verlag
Springer US
Erschienen in
Journal of Interventional Cardiac Electrophysiology / Ausgabe 3/2019
Print ISSN: 1383-875X
Elektronische ISSN: 1572-8595
DOI
https://doi.org/10.1007/s10840-019-00574-3

Weitere Artikel der Ausgabe 3/2019

Journal of Interventional Cardiac Electrophysiology 3/2019 Zur Ausgabe

OriginalPaper

The use of a high-resolution mapping system may facilitate standard clinical practice in VE and VT ablation

OriginalPaper

Long-term performance of right ventricular pacing leads: risk factors associated with permanent right ventricular pacing threshold increase

OriginalPaper

Cryoballoon ablation of atrial fibrillation is effectively feasible without previous imaging of pulmonary vein anatomy: insights from the 1STOP project

MULTIMEDIA REPORT

Predictors of 30-day readmissions after catheter ablation for atrial fibrillation in the USA

OriginalPaper

The modified ablation index: a novel determinant of acute pulmonary vein reconnections after pulmonary vein isolation

MULTIMEDIA REPORT

The role of microRNAs in the development, regulation, and treatment of atrial fibrillation

Neu im Fachgebiet Kardiologie

19.04.2024 | Vorhofflimmern | Nachrichten

Parodontalbehandlung verbessert Prognose bei Katheterablation

18.04.2024 | Arterielle Hypertonie | Nachrichten

Antihypertensiva schützen auch alte Menschen noch vor Demenz

16.04.2024 | Chronische Herzinsuffizienz | Nachrichten

Sind Betablocker auch für ältere herzschwache Personen nützlich?

16.04.2024 | Stillen, Säuglingsnahrung, Beikost | Nachrichten

Stillende Frauen haben geringeres kardiovaskuläres Risiko
weitere anzeigen

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen